Document is current
Any future updates will be listed below
-
Authors
Green, Mark A.
Hungerford, Daniel J.
Hughes, David M.
Garcia-Fiñana, Marta
Turtle, Lance
Cheyne, Christopher
Ashton, Matthew
Leeming, Gary
Semple, Malcolm G.
Singleton, Alex
Buchan, Iain
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/W021242/1, MR/R024847/1)
National Institute for Health Research (NIHR200910, NIHR200907)
- License Information
-
More Information
Article History
Received: 27 May 2022
Accepted: 14 November 2022
First Online: 26 November 2022
Declarations
:
: Ethical approval was granted by the University of Liverpool’s Research Ethics committee (REF: 10634). Data access was granted by the CIPHA Information Governance panel and Liverpool Clinical Commissioning Group as part of the COVID-19 response work the team were involved in. All data accessed were pseudo-anonymised prior to use.
: Not applicable.
: IB declares grants from NIHR, personal fees and other from AstraZeneca, outside the submitted work. MGS declares non-remunerated participation on Pfizer’s External Data Monitoring Committee for their mRNA vaccine programmes. MGS holds stocks in Integrum Scientific LLC and MedEx Solutions Ltd. MGS also declares being a non-remunerated independent member of the UK Government’s SAGE and NERVTAG groups. No further conflicts of interest are declared.
